| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3391208 | Seminarios de la Fundación Española de Reumatología | 2009 | 7 Pages |
Abstract
Consequently, there is clearly a need for further well-designed studies of the most recent therapeutic options. Equally, control of cardiovascular risk factors and the use of additional therapies that avoid the adverse effects of these immunosuppressive agents are required to improve the management of patients with type IV lupus nephritis.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Juan Ignacio Villa Blanco, VÃctor Manuel MartÃnez Taboada,